Early-stage preclinical research on hantavirus vaccine candidates, including mRNA platforms from Moderna and Korea University plus structural designs from University of Texas teams, underpins the 94.5% market-implied odds against approval in 2026. No orthohantavirus vaccine has received FDA, WHO, or broad international licensure outside limited use of older candidates like Hantavax in South Korea, and no Phase 3 efficacy trials are active. Vaccine development timelines typically require years of human testing after promising rodent data, with challenges including low disease incidence limiting field studies and variable strain coverage. New model systems or funding surges could accelerate progress, but current trajectories make 2026 approval improbable.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoHantavirus vaccine in 2026?
$129,605 Wol.
$129,605 Wol.
$129,605 Wol.
$129,605 Wol.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Rynek otwarty: May 4, 2026, 10:39 AM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Resolver
0x65070BE91...Early-stage preclinical research on hantavirus vaccine candidates, including mRNA platforms from Moderna and Korea University plus structural designs from University of Texas teams, underpins the 94.5% market-implied odds against approval in 2026. No orthohantavirus vaccine has received FDA, WHO, or broad international licensure outside limited use of older candidates like Hantavax in South Korea, and no Phase 3 efficacy trials are active. Vaccine development timelines typically require years of human testing after promising rodent data, with challenges including low disease incidence limiting field studies and variable strain coverage. New model systems or funding surges could accelerate progress, but current trajectories make 2026 approval improbable.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano



Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania